Literature DB >> 24122720

MicroRNA-124 controls the proliferative, migratory, and inflammatory phenotype of pulmonary vascular fibroblasts.

Daren Wang1, Hui Zhang, Min Li, Maria G Frid, Amanda R Flockton, B Alexandre McKeon, Michael E Yeager, Mehdi A Fini, Nicholas W Morrell, Soni S Pullamsetti, Sivareddy Velegala, Werner Seeger, Timothy A McKinsey, Carmen C Sucharov, Kurt R Stenmark.   

Abstract

RATIONALE: Pulmonary hypertensive remodeling is characterized by excessive proliferation, migration, and proinflammatory activation of adventitial fibroblasts. In culture, fibroblasts maintain a similar activated phenotype. The mechanisms responsible for generation/maintenance of this phenotype remain unknown.
OBJECTIVE: We hypothesized that aberrant expression of microRNA-124 (miR-124) regulates this activated fibroblast phenotype and sought to determine the signaling pathways through which miR-124 exerts effects. METHODS AND
RESULTS: We detected significant decreases in miR-124 expression in fibroblasts isolated from calves and humans with severe pulmonary hypertension. Overexpression of miR-124 by mimic transfection significantly attenuated proliferation, migration, and monocyte chemotactic protein-1 expression of hypertensive fibroblasts, whereas anti-miR-124 treatment of control fibroblasts resulted in their increased proliferation, migration, and monocyte chemotactic protein-1 expression. Furthermore, the alternative splicing factor, polypyrimidine tract-binding protein 1, was shown to be a direct target of miR-124 and to be upregulated both in vivo and in vitro in bovine and human pulmonary hypertensive fibroblasts. The effects of miR-124 on fibroblast proliferation were mediated via direct binding to the 3' untranslated region of polypyrimidine tract-binding protein 1 and subsequent regulation of Notch1/phosphatase and tensin homolog/FOXO3/p21Cip1 and p27Kip1 signaling. We showed that miR-124 directly regulates monocyte chemotactic protein-1 expression in pulmonary hypertension/idiopathic pulmonary arterial hypertension fibroblasts. Furthermore, we demonstrated that miR-124 expression is suppressed by histone deacetylases and that treatment of hypertensive fibroblasts with histone deacetylase inhibitors increased miR-124 expression and decreased proliferation and monocyte chemotactic protein-1 production.
CONCLUSIONS: Stable decreases in miR-124 expression contribute to an epigenetically reprogrammed, highly proliferative, migratory, and inflammatory phenotype of hypertensive pulmonary adventitial fibroblasts. Thus, therapies directed at restoring miR-124 function, including histone deacetylase inhibitors, should be investigated.

Entities:  

Keywords:  anoxia; hypertension, pulmonary; migration; neoplasms; proliferation

Mesh:

Substances:

Year:  2013        PMID: 24122720      PMCID: PMC4117588          DOI: 10.1161/CIRCRESAHA.114.301633

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  80 in total

Review 1.  Protein acetylation in the cardiorenal axis: the promise of histone deacetylase inhibitors.

Authors:  Erik W Bush; Timothy A McKinsey
Journal:  Circ Res       Date:  2010-02-05       Impact factor: 17.367

2.  Downregulation of miR-124 promotes the growth and invasiveness of glioblastoma cells involving upregulation of PPP1R13L.

Authors:  Wei-Hua Zhao; Sheng-Qi Wu; Yang-De Zhang
Journal:  Int J Mol Med       Date:  2013-04-29       Impact factor: 4.101

3.  Antifibrotic activity of an inhibitor of histone deacetylases in DOCA-salt hypertensive rats.

Authors:  Abishek Iyer; Andrew Fenning; Junxian Lim; Giang T Le; Robert C Reid; Maria A Halili; David P Fairlie; Lindsay Brown
Journal:  Br J Pharmacol       Date:  2010-02-24       Impact factor: 8.739

4.  A role for miR-145 in pulmonary arterial hypertension: evidence from mouse models and patient samples.

Authors:  Paola Caruso; Yvonne Dempsie; Hannah C Stevens; Robert A McDonald; Lu Long; Ruifang Lu; Kevin White; Kirsty M Mair; John D McClure; Mark Southwood; Paul Upton; Mei Xin; Eva van Rooij; Eric N Olson; Nicholas W Morrell; Margaret R MacLean; Andrew H Baker
Journal:  Circ Res       Date:  2012-06-19       Impact factor: 17.367

5.  HDAC inhibitors as anti-inflammatory agents.

Authors:  I M Adcock
Journal:  Br J Pharmacol       Date:  2007-02-26       Impact factor: 8.739

6.  Ephrin-B1 reverse signaling controls a posttranscriptional feedback mechanism via miR-124.

Authors:  Dina N Arvanitis; Thomas Jungas; Annie Behar; Alice Davy
Journal:  Mol Cell Biol       Date:  2010-03-22       Impact factor: 4.272

7.  Impact of HIF-1alpha and HIF-2alpha on proliferation and migration of human pulmonary artery fibroblasts in hypoxia.

Authors:  Bastian Eul; Frank Rose; Stefanie Krick; Rajkumar Savai; Parag Goyal; Walter Klepetko; Friedrich Grimminger; Norbert Weissmann; Werner Seeger; Jörg Hänze
Journal:  FASEB J       Date:  2005-11-01       Impact factor: 5.191

8.  Expression and function of histone deacetylases in rheumatoid arthritis synovial fibroblasts.

Authors:  Marika Horiuchi; Akio Morinobu; Takaaki Chin; Yoshitada Sakai; Masahiro Kurosaka; Shunichi Kumagai
Journal:  J Rheumatol       Date:  2009-06-16       Impact factor: 4.666

9.  MicroRNA and target protein patterns reveal physiopathological features of glioma subtypes.

Authors:  Elodie Lages; Audrey Guttin; Michèle El Atifi; Claire Ramus; Hélène Ipas; Isabelle Dupré; Delphine Rolland; Caroline Salon; Catherine Godfraind; Florence deFraipont; Mehdi Dhobb; Laurent Pelletier; Didier Wion; Emmanuel Gay; François Berger; Jean-Paul Issartel
Journal:  PLoS One       Date:  2011-05-31       Impact factor: 3.240

Review 10.  Scleroderma pathogenesis: a pivotal role for fibroblasts as effector cells.

Authors:  Adrian J Gilbane; Christopher P Denton; Alan M Holmes
Journal:  Arthritis Res Ther       Date:  2013       Impact factor: 5.156

View more
  78 in total

1.  Matrix Remodeling Promotes Pulmonary Hypertension through Feedback Mechanoactivation of the YAP/TAZ-miR-130/301 Circuit.

Authors:  Thomas Bertero; Katherine A Cottrill; Yu Lu; Christina M Haeger; Paul Dieffenbach; Sofia Annis; Andrew Hale; Balkrishen Bhat; Vivek Kaimal; Ying-Yi Zhang; Brian B Graham; Rahul Kumar; Rajan Saggar; Rajeev Saggar; W Dean Wallace; David J Ross; Stephen M Black; Sohrab Fratz; Jeffrey R Fineman; Sara O Vargas; Kathleen J Haley; Aaron B Waxman; B Nelson Chau; Laura E Fredenburgh; Stephen Y Chan
Journal:  Cell Rep       Date:  2015-10-22       Impact factor: 9.423

Review 2.  Metabolic reprogramming and inflammation act in concert to control vascular remodeling in hypoxic pulmonary hypertension.

Authors:  Kurt R Stenmark; Rubin M Tuder; Karim C El Kasmi
Journal:  J Appl Physiol (1985)       Date:  2015-04-30

Review 3.  Mechanisms and therapeutic potential of microRNAs in hypertension.

Authors:  Lijun Shi; Jingwen Liao; Bailin Liu; Fanxing Zeng; Lubo Zhang
Journal:  Drug Discov Today       Date:  2015-05-21       Impact factor: 7.851

Review 4.  Emerging roles for histone deacetylases in pulmonary hypertension and right ventricular remodeling (2013 Grover Conference series).

Authors:  Maria A Cavasin; Kurt R Stenmark; Timothy A McKinsey
Journal:  Pulm Circ       Date:  2015-03       Impact factor: 3.017

Review 5.  Translational Advances in the Field of Pulmonary Hypertension. Focusing on Developmental Origins and Disease Inception for the Prevention of Pulmonary Hypertension.

Authors:  Bradley A Maron; Steven H Abman
Journal:  Am J Respir Crit Care Med       Date:  2017-02-01       Impact factor: 21.405

6.  Rosiglitazone Inhibits Activation of Hepatic Stellate Cells via Up-Regulating Micro-RNA-124-3p to Alleviate Hepatic Fibrosis.

Authors:  Shao-Ce Zhi; Shi-Zuan Chen; Yan-Yan Li; Jun-Jian Li; Yi-Hu Zheng; Fu-Xiang Yu
Journal:  Dig Dis Sci       Date:  2019-01-23       Impact factor: 3.199

7.  Estrogen Metabolite 16α-Hydroxyestrone Exacerbates Bone Morphogenetic Protein Receptor Type II-Associated Pulmonary Arterial Hypertension Through MicroRNA-29-Mediated Modulation of Cellular Metabolism.

Authors:  Xinping Chen; Megha Talati; Joshua P Fessel; Anna R Hemnes; Santhi Gladson; Jaketa French; Sheila Shay; Aaron Trammell; John A Phillips; Rizwan Hamid; Joy D Cogan; Elliott P Dawson; Kristie E Womble; Lora K Hedges; Elizabeth G Martinez; Lisa A Wheeler; James E Loyd; Susan J Majka; James West; Eric D Austin
Journal:  Circulation       Date:  2015-10-20       Impact factor: 29.690

Review 8.  MicroRNAs in respiratory disease. A clinician's overview.

Authors:  Derek Brown; Mohammad Rahman; S Patrick Nana-Sinkam
Journal:  Ann Am Thorac Soc       Date:  2014-10

Review 9.  Pulmonary arterial hypertension: pathogenesis and clinical management.

Authors:  Thenappan Thenappan; Mark L Ormiston; John J Ryan; Stephen L Archer
Journal:  BMJ       Date:  2018-03-14

10.  Metabolic Reprogramming Regulates the Proliferative and Inflammatory Phenotype of Adventitial Fibroblasts in Pulmonary Hypertension Through the Transcriptional Corepressor C-Terminal Binding Protein-1.

Authors:  Min Li; Suzette Riddle; Hui Zhang; Angelo D'Alessandro; Amanda Flockton; Natalie J Serkova; Kirk C Hansen; Radu Moldovan; B Alexandre McKeon; Maria Frid; Sushil Kumar; Hong Li; Hongbing Liu; Angela Caánovas; Juan F Medrano; Milton G Thomas; Dijana Iloska; Lydie Plecitá-Hlavatá; Petr Ježek; Soni Pullamsetti; Mehdi A Fini; Karim C El Kasmi; QingHong Zhang; Kurt R Stenmark
Journal:  Circulation       Date:  2016-08-25       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.